" class="no-js "lang="en-US"> Chloe MacArthur - Medtech Alert
Tuesday, April 29, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Chloe MacArthur

Chloe MacArthur

About Chloe MacArthur

I’m a Senior Cardiac Nurse on the Clinical team at the BHF, taking calls from people affected by cardiovascular disease on our helpline, responding to media queries and providing clinical input to teams across the BHF to support the work that we do.

Related Story

Cardiovascular

 Spending Less Time Watching TV Could Cut Coronary Heart Disease Risk | Pharmtech Focus

Spending Less Time Watching TV Could Cut Coronary Heart Disease Risk

May 25 2022

Watching too much TV is associated with an increased risk of coronary heart disease regardless […]